Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer

Philipp Harter, Fabian Trillsch, Aikou Okamoto, A. Reuss, Ji‐Hoon Kim, María Jesús Rubio-Pérez, Mehmet Ali Vardar, G Scambia, Olivier Trédan, Gitte-Bettina Nyvang, N. Colombo, Mariusz Bidziński, Christoph Grimm, S. Lheureux, Els Van Nieuwenhuysen, Florian Heitz, Robert M. Wenham, Shin Nishio, Myong Cheol Lim, Gloria Marquina, Özden Altundağ, Alice Bergamini, Renaud Sabatier, P. Wimberger, Michael A. Gold, J. Sehouli, Tjoung‐Won Park‐Simon, Erin E. Kent, A. Correa, C. Aghajanian